Literature DB >> 12239091

Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death.

Wenli Liu1, Catherine Chin-Chance, Eun-Jig Lee, William L Lowe.   

Abstract

To begin to determine whether IGF-I treatment represents a potential means of enhancing the survival of islet cell grafts after transplantation, the present studies established a model of beta-cell death secondary to loss of trophic support and examined the ability of IGF-I to prevent cell death. The studies were performed using the rat pancreatic beta-cell line, INS-1. Incubating INS-1 cells in RPMI 1640 and 0.25% BSA for 48 h increased cell death, as determined by lactate dehydrogenase release, compared with that of cells maintained in RPMI and 10% fetal calf serum. Addition of 100 ng/ml IGF-I to the serum-free medium decreased lactate dehydrogenase release to a level comparable to that found in cells maintained in fetal calf serum. Similar results were seen using a mouse beta-cell line, MIN6, infected with an adenovirus expressing IGF-I. Examination of IGF-I-stimulated signaling demonstrated that IGF-I increased the phosphorylation of protein kinase B in both cell lines, whereas IGF-I-induced phosphorylation of the MAPKs, ERK1 and -2, was observed only in INS-1 cells. The effect of IGF-I on phosphorylation of substrates of phosphatidylinositol 3-kinase (PI 3-kinase) or protein kinase B was also examined in INS-1 cells. IGF-I increased the phosphorylation of glycogen synthase kinase 3beta, BAD, FKHR, and p70(S6) kinase. Another pathway that has been shown to mediate the protective of IGF-I in some cell types is activation of cAMP response element-binding protein (CREB). IGF-I increased CREB phosphorylation at a concentration as low as 10 ng/ml, and this effect was inhibited by H89, a PKA inhibitor, and PD98059, a MAPK kinase inhibitor. Consistent with the effect of IGF-I on CREB phosphorylation, IGF-I increased the transcriptional activity of CREB, although it had no effect on CREB binding to DNA. Use of inhibitors of the PI 3-kinase (LY 294002) or ERK (PD98059) pathways or CREB phosphorylation (H89) in the cell death assay demonstrated partial abrogation of the protective effect of IGF-I with LY 294002. These data demonstrate that IGF-I protects pancreatic beta-cells from cell death secondary to loss of trophic support and that, although IGF-I activates several signaling pathways that contribute to its protective effect in other cell types, only activation of PI 3-kinase contributes to this effect in beta-cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239091     DOI: 10.1210/en.2002-220058

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Autocrine insulin action activates Akt and increases survival of isolated human islets.

Authors:  R Aikin; S Hanley; D Maysinger; M Lipsett; M Castellarin; S Paraskevas; L Rosenberg
Journal:  Diabetologia       Date:  2006-10-20       Impact factor: 10.122

2.  Age-related decline in osteoblastogenesis and 1α-hydroxylase/CYP27B1 in human mesenchymal stem cells: stimulation by parathyroid hormone.

Authors:  Shuo Geng; Shuanhu Zhou; Julie Glowacki
Journal:  Aging Cell       Date:  2011-08-24       Impact factor: 9.304

3.  Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study.

Authors:  A M Arafat; M Möhlig; M O Weickert; C Schöfl; J Spranger; A F H Pfeiffer
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

4.  A selective human bombesin receptor subtype-3 peptide agonist mediates CREB phosphorylation and transactivation.

Authors:  Xiaoqun Qin; Xiangping Qu; David Coy; H Christian Weber
Journal:  J Mol Neurosci       Date:  2011-11-30       Impact factor: 3.444

5.  Prostaglandin E2 regulates Foxo activity via the Akt pathway: implications for pancreatic islet beta cell dysfunction.

Authors:  Z X Meng; J X Sun; J J Ling; J H Lv; D Y Zhu; Q Chen; Y J Sun; X Han
Journal:  Diabetologia       Date:  2006-10-11       Impact factor: 10.122

Review 6.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

7.  Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes.

Authors:  Bangyan L Stiles; Christine Kuralwalla-Martinez; Wei Guo; Caroline Gregorian; Ying Wang; Jide Tian; Mark A Magnuson; Hong Wu
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

8.  Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11.

Authors:  S Dhayal; H J Welters; N G Morgan
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

9.  Rapamycin inhibits growth factor-induced cell cycle regulation in pancreatic beta cells.

Authors:  Amy Aronovitz; Jami Josefson; Amanda Fisher; Marsha Newman; Elizabeth Hughes; Fei Chen; David S Moons; Hiroaki Kiyokawa; William L Lowe
Journal:  J Investig Med       Date:  2008-12       Impact factor: 2.895

10.  Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop.

Authors:  Marion Cornu; Jiang-Yan Yang; Evrim Jaccard; Carine Poussin; Christian Widmann; Bernard Thorens
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.